-
-
Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in randomised trials dedicated to PS2 patients. High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. Another research priority is the improvement of supportive care.
-
In a randomized clinical trial involving 773 patients, 4mg or 8mg of zoledronate were compared with placebo in patients with bone metastases from solid tumors (other than breast or prostate cancer). Fewer patients treated with zoledronate developed 1 or more skeletal related events (pathologic fracture, spinal cord compression, radiation therapy to bone, and surgery to bone) at 21 months of treatment.
-
-
In a prospective, randomized trial, primary excision of colorectal carcinomas by laparoscopic surgery was compared with laparotomy. Disease recurrence and 5-year survival were not significantly different in the 2 groups. Operative time was greater for those receiving laparoscopic approach but post-operative recovery and hospital stays were shorter.
-
In an analysis of seven CALGB acute myelogenous leukemia trials that accrued patients over a 13 year period (1985-1997), complete remission rates and overall survival were found to be worse for African American men, when compared to white men or women or African American women.
-
Patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology.
-
FDA Rejects Plan B Bid; Recombinant Erythropoietin Products May Stimulate Tumor Growth; Rosuvastatin: Markets Most Potent Statin; FDA Actions.
-
-
